BAFNA PHARMACEUTICALS
|
BAFNA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 |
CEPS(Rs) | 3.82 | 5.22 | 7.05 | 4.53 | 4.36 |
DPS(Rs) | - | - | - | - | - |
Book NAV/Share(Rs) | 35.85 | 34.17 | 31.05 | 26.19 | 24.00 |
Tax Rate(%) | - | - | 2.40 | - | - |
Margin Ratios | |||||
Core EBITDA Margin(%) | 7.46 | 7.29 | 13.62 | 13.98 | 14.46 |
EBIT Margin(%) | 4.72 | 6.32 | 11.84 | 7.06 | 9.22 |
Pre Tax Margin(%) | 2.85 | 4.82 | 10.07 | 6.13 | 8.18 |
PAT Margin (%) | 2.85 | 4.82 | 9.83 | 6.13 | 8.18 |
Cash Profit Margin (%) | 6.20 | 8.10 | 14.45 | 12.58 | 14.47 |
Performance Ratios | |||||
ROA(%) | 2.76 | 5.30 | 10.32 | 5.91 | 7.40 |
ROE(%) | 5.01 | 9.52 | 16.75 | 8.79 | 22.26 |
ROCE(%) | 6.31 | 9.56 | 16.12 | 8.42 | 10.62 |
Asset Turnover(x) | 0.97 | 1.10 | 1.05 | 0.96 | 0.90 |
Sales/Fixed Asset(x) | 1.42 | 1.57 | 1.26 | 1.02 | 0.93 |
Working Capital/Sales(x) | 4.44 | 3.84 | 2.82 | 2.95 | 2.81 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.70 | 0.64 | 0.79 | 0.98 | 1.08 |
Receivable days | 107.07 | 103.59 | 88.49 | 52.17 | 39.96 |
Inventory Days | 72.23 | 62.08 | 67.24 | 76.57 | 68.82 |
Payable days | 149.66 | 134.43 | 118.26 | 105.56 | 133.55 |
Valuation Parameters | |||||
PER(x) | 42.73 | 24.68 | 17.24 | 57.59 | 55.74 |
PCE(x) | 19.62 | 14.69 | 11.73 | 28.05 | 31.52 |
Price/Book(x) | 2.09 | 2.24 | 2.66 | 4.85 | 5.72 |
Yield(%) | - | - | - | - | - |
EV/Net Sales(x) | 1.39 | 1.34 | 1.83 | 3.66 | 4.72 |
EV/Core EBITDA(x) | 14.53 | 13.96 | 11.09 | 22.79 | 30.42 |
EV/EBIT(x) | 29.37 | 21.20 | 15.43 | 51.80 | 51.15 |
EV/CE(x) | 1.79 | 1.94 | 2.19 | 3.45 | 3.89 |
M Cap / Sales | 1.22 | 1.19 | 1.70 | 3.53 | 4.56 |
Growth Ratio | |||||
Net Sales Growth(%) | -4.33 | 32.18 | 35.48 | 19.55 | 67.68 |
Core EBITDA Growth(%) | -4.88 | -22.93 | 39.00 | 23.66 | 644.34 |
EBIT Growth(%) | -28.58 | -29.41 | 127.17 | -8.50 | 468.50 |
PAT Growth(%) | -43.49 | -35.19 | 117.34 | -10.47 | 410.26 |
EPS Growth(%) | -43.49 | -35.19 | 117.34 | -10.47 | 131.03 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.33 | 0.30 | 0.31 | 0.18 | 0.23 |
Current Ratio(x) | 1.63 | 1.73 | 1.88 | 2.31 | 2.04 |
Quick Ratio(x) | 1.09 | 1.19 | 1.40 | 1.39 | 1.41 |
Interest Cover(x) | 2.52 | 4.21 | 6.70 | 7.57 | 8.85 |
Total Debt/Mcap(x) | 0.16 | 0.13 | 0.12 | 0.04 | 0.04 |
Compare Financial Ratios of peers of BAFNA PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
BAFNA PHARMACEUTICALS | ₹366.5 Cr | -7.7% | 37.5% | 87.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹405,560.0 Cr | 2.2% | 2.1% | -10.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹175,033.0 Cr | 0.3% | 6.4% | 8.7% | Stock Analytics | |
CIPLA | ₹134,400.0 Cr | 6.8% | 5.6% | 5.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹121,507.0 Cr | 1.6% | -1.1% | 5.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹107,628.0 Cr | 4.6% | -2.5% | -4.3% | Stock Analytics |
BAFNA PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
BAFNA PHARMACEUTICALS | -7.7% |
37.5% |
87.9% |
SENSEX | 2.9% |
1.7% |
3.6% |
You may also like the below Video Courses